Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
169.71-1.92 (-1.12%)
At close: 4:00 PM EDT

169.71 0.00 (0.00%)
After hours: 5:06 PM EDT

People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open172.22
Prev Close171.63
Bid169.60 x 4000
Ask170.20 x 3400
Day's Range169.05 - 172.22
52wk Range135.64 - 176.85
1y Target EstN/A
Market Cap127B
P/E Ratio (ttm)17.37
Beta1.34
Volume2,961,818
Avg Vol (3m)2,857,300
Dividend & Yield4.00 (2.31%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire43 minutes ago

    Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

    THOUSAND OAKS, Calif., Sept. 28, 2016 /PRNewswire/ -- Amgen (AMGN) today announced positive top-line results for erenumab (AMG 334) from A Phase 3, RandomIzed, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of erenumab in migraine prevention (ARISE). Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine. "People with episodic migraine lose a substantial part of their lives to migraine, and many face intolerable pain and physical impairment, frequently accompanied by a significant disruption of their daily activities.

  • Investopedia5 hours ago

    3 Nasdaq-100 Stocks Ready to Play Catch-Up

    These Nasdaq-100 components show stronger buying interest than price gains, predicting the price will play catch up in coming months.

  • TheStreet.com5 hours ago

    Four Stellar Stocks to Beat the Biotech Slump

    Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum